Moderna’s mRNA Candidate Joins FDA’s Accelerator Program for Rare Diseases

cafead

Administrator
Staff member
  • cafead   Jun 06, 2024 at 11:42: AM
via Moderna on Thursday announced that the FDA has selected its investigational methylmalonic acidemia therapy mRNA-3705 for the agency’s Support for Clinical Trials Advancing Rare Disease Therapeutics pilot program.

article source
 

<